Pregnancy outcomes and adverse events of Fondaparinux and Low Molecular-Weight Heparin in Recurrent Miscarriage

The superiority of fondaparinux over low molecular weight heparin (LMWH) in treating recurrent miscarriages is debatable. The present study comprehensively compared the pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus LMWH by searching the reputed databases.

The study observed-

• Enrollment of 321 patients receiving fondaparinux and 546 patients receiving LMWH. 
• Similar incidences of Live birth, abortion, birth weight, and Fetal growth restriction (FGR) between patients receiving fondaparinux and LMWH. 
• Lower incidence of ecchymosis and skin reaction at the injection site in patients receiving fondaparinux compared with those receiving LMWH.
• Similar incidences of thrombocytopenia, vagina bleeding, and oral mucosa hemorrhage between patients receiving these two treatments.
• Most studies were from China, which could induce regional and ethnic bias.

This study demonstrates that Fondaparinux has fewer adverse events and comparable pregnancy outcomes to LMWH in patients with recurrent miscarriage.

Mu F, Wang M, Huang J, Wang F. Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: A meta-analysis. EJOG. 2023;287:29-35. DOI:https://doi.org/10.1016/j.ejogrb.2023.05.031